Clinical Trials Logo

Filter by:
NCT ID: NCT05836727 Active, not recruiting - Pelvic Fracture Clinical Trials

Use of Laparoscopy in the Treatment of Pelvic Ring Ruptures

PELVICOELIO
Start date: March 1, 2023
Phase:
Study type: Observational

Case series to describe the use of laparoscopy for the treatment of pelvic ring disruption.

NCT ID: NCT05836324 Recruiting - Solid Tumors Clinical Trials

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Start date: July 24, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

NCT ID: NCT05835973 Not yet recruiting - Ulcerative Colitis Clinical Trials

Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.

RECIDREAM
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Inflammatory Bowel Diseases (IBD) go through two phases: flare and remission. Prediction of flares and identification of patients in remission but at high risk of flare are a major issue when taking care of IBD patients. Considering close interactions between sleep, immunity and intestinal inflammation, sleep disorders could be a predictor of flares. The purpose of this study is to demonstrate that sleep efficacy decreases before IBD flare. Patients in remission will be assessed for IBD symptoms (activity scores, biological factors) and sleep disorders (actigraphy, DREEM®, questionnaires) during one year.

NCT ID: NCT05835908 Completed - Unscheduled Care Clinical Trials

Follow-up of Patients Referred to Unscheduled Care Centers by the Emergency Call Center in the Haut-Rhin Department, France

CSNP68
Start date: May 17, 2023
Phase:
Study type: Observational

The objective of this study is to determine the follow-up of patients who were referred by the Emergency Call Center of the Haut-Rhin department to an Unscheduled Care Centers (UCC) and to determine whether they actuallly went to a UCC following their call, or if they were taken in charge by another care facility.

NCT ID: NCT05835856 Active, not recruiting - Quality of Life Clinical Trials

e-VITA: European-Japanese Virtual Coach for Smart Ageing (WAVE II)

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The study is a multicentre Proof-of-Concept. The general objective of the e-VITA project is to develop a personalized virtual coach capable of interacting with its elderly interlocutor. The experimentation will be carried out in 4 sites: Italy, France, Germany and Japan.

NCT ID: NCT05835817 Recruiting - Premature Clinical Trials

Magnetoencephalography by Optical Pumping Magnetometer

MEG OPM
Start date: May 2023
Phase: N/A
Study type: Interventional

MagnetoEncephaloGraphy (MEG) is a method of recording brain activity with high temporal resolution and good spatial resolution, compared to current recording techniques such as ElectroEncephaloGraphy (EEG). The main limitation of MEG is its cost due to the sensors used, the Super Quantum Interference Devices (SQUID). These require a complex infrastructure from an instrumentation point of view to operate, requiring liquid helium, most often at a loss, at increasing cost. Optical Pumping Magnetometers (OPM) type sensors represent a promising alternative to SQUIDs sensors, especially since they do not require helium cooling. The purpose of this project is to Identify biomarkers in Magnetoencephalography of normal brain development in healthy adults, premature and term newborns from "a priori" obtained by the classical technique of High Resolution EEG performed.

NCT ID: NCT05835804 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers

NIVOCHIMLOC
Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Patients with locally recurrent squamous-cell carcinoma of the head and neck (SCCHN) after Chemotherapy and immunotherapy have a very poor prognosis and limited therapeutic options. Intratumoral chemotherapy (ITC) with cisplatin and epinephrine in order to increase the local cisplatin retention lead to a 50 % response rate in several studies but was given up due to the poor local tolerance with frequent necrosis of the peritumoral tissues. Gemcitabine, carboplatin and paclitaxel (GCP) are used in advanced SCCHN. These chemotherapies seem to be interesting options for intratumoral infusion: their different effect could lead to avoid chemotherapy resistance with a good tolerance profile, without tissue necrosis profile. The other major option for recurrent SCCHN is immunotherapy by Nivolumab, an anti PD-1 with a 13% mediane response rate. Nevertheless, the failure of this treatment stay unclear, but immunosuppressive action of the tumour is suspected. The presence of tumoral antigen could lead to better response to immunotherapy; association of chemotherapy and immunotherapy seems a promosing association to avoid treatment resistance as cytotoxic release tumoral antigen; it could also be associated to an abscopal effect. The aim of the study is to evaluate the efficacy of ITC using GCP in LOCAL recurrent SCCHN treated by nivolumab.

NCT ID: NCT05835622 Not yet recruiting - Multiple Sclerosis Clinical Trials

Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.

EXHOMESEP
Start date: May 2, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to evaluate the effectiveness of home use of a lightweight robotic lower limb exoskeleton as a walking aid device on quality of life in patients with multiple sclerosis with gait disorders. Participants will wear an exoskeleton (Keeogo) for 8 weeks at home during the experimental phase. This phase is compared to an 8-week control phase at home with advice on regular physical activity adapted to their abilities.

NCT ID: NCT05835310 Recruiting - Clinical trials for Systemic Lupus Erythematosus

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

SLE
Start date: March 14, 2024
Phase: Phase 3
Study type: Interventional

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE

NCT ID: NCT05833880 Completed - Atopic Dermatitis Clinical Trials

Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis

Start date: May 10, 2023
Phase:
Study type: Observational

Complementary and alternative medicine are increasingly used all around the world and more specifically in chronic diseases such as atopic dermatitis. Sociodemographic and disease determinants associated with their use remain unclear. Moreover, most of studies involved children and little data are available for adults. The main objective of this study is to identify factors associated with complementary and alternative medicine use in children and adults suffering from atopic dermatitis. The secondary objectives are to determine the prevalence of complementary and alternative medicine use, the main forms used and their modalities of use, patients' motivations for using these therapies and sources of information. Patients of all ages consulting for their atopic dermatitis at the dermatology or pediatric allergology department of Nancy University Hospital over a 6 months period will be asked to fill out a questionnaire about their pathology and their use of complementary and alternative medicine. This questionnaire will be collected before they leave the hospital.